File:Cyclophosphamide-2000-results.png: Difference between revisions
Notjusttired (talk | contribs) m (Text replacement - "|first3=" to " | first3 = ") |
Notjusttired (talk | contribs) m (Text replacement - "|author-link6=" to " | authorlink6 = ") |
||
Line 7: | Line 7: | ||
(C): mean steps per 24hrs; | (C): mean steps per 24hrs; | ||
CI: confidence intervals.<br/> | CI: confidence intervals.<br/> | ||
Numbers of patients at the different time points through follow-up are shown below the graphs.<ref name="Rekeland2020">{{Cite journal|last=Rekeland | first=Ingrid G.|author-link= | last2 = Fosså | first2 = Alexander|author-link2= | last3 = Lande | first3 = Asgeir|author-link3= | last4 = Ktoridou-Valen | first4 = Irini|author-link4= | last5 = Sørland | first5=Kari | authorlink5 = | last6 = Holsen | first6 = Mari| | Numbers of patients at the different time points through follow-up are shown below the graphs.<ref name="Rekeland2020">{{Cite journal|last=Rekeland | first=Ingrid G.|author-link= | last2 = Fosså | first2 = Alexander|author-link2= | last3 = Lande | first3 = Asgeir|author-link3= | last4 = Ktoridou-Valen | first4 = Irini|author-link4= | last5 = Sørland | first5=Kari | authorlink5 = | last6 = Holsen | first6 = Mari | authorlink6 = |last7 = Tronstad | first7=Karl J. | authorlink7 = Karl Tronstad|last8 = Risa | first8 = Kristin | authorlink8 = |last9 = Alme | first9 = Kine | authorlink9 = |date=2020|title=Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study|url=https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full|journal=Frontiers in Medicine|language=English|volume=7|issue=162|pages=|doi=10.3389/fmed.2020.00162|issn=2296-858X|pmc=|pmid=|access-date=|quote=|via=|last10 = Viken | first10 = Marte K.|author-link10= | last11 = Lie | first11= Benedicte K.|author-link11= | last12 = Dahl | first12 = Olav|author-link12= | last13 = Mella | first13 = Olav|author-link13=Olav Mella | first14 = Øystein | last14 = Fluge|author-link14=Øystein Fluge}}</ref> | ||
==== Author: (or citation) ==== | ==== Author: (or citation) ==== | ||
{{Cite journal|vauthors=Rekeland IG, Fosså A, Lande A, Ktoridou-Valen I, Sørland K, Holsen M, Tronstad KJ, Risa K, Alme K, Viken MK, Lie BA, Dahl O, Mella O, Fluge Ø|date=2020|title=Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study|url=https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full|journal=Front. Med.|language=English|volume=7|pages=162|doi=10.3389/fmed.2020.00162|pmc=|pmid=}} | {{Cite journal|vauthors=Rekeland IG, Fosså A, Lande A, Ktoridou-Valen I, Sørland K, Holsen M, Tronstad KJ, Risa K, Alme K, Viken MK, Lie BA, Dahl O, Mella O, Fluge Ø|date=2020|title=Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study|url=https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full|journal=Front. Med.|language=English|volume=7|pages=162|doi=10.3389/fmed.2020.00162|pmc=|pmid=}} |
Revision as of 01:26, December 1, 2022
Summary[edit | edit source]
Title: (or description)[edit | edit source]
Cyclophosphamide ME/CFS trial results extended follow-up.
Key:
(A): SF-36 Physical Function (SF-36-PF);
(B) percent function level;
(C): mean steps per 24hrs;
CI: confidence intervals.
Numbers of patients at the different time points through follow-up are shown below the graphs.[1]
Author: (or citation)[edit | edit source]
Rekeland IG, Fosså A, Lande A, Ktoridou-Valen I, Sørland K, Holsen M, Tronstad KJ, Risa K, Alme K, Viken MK, Lie BA, Dahl O, Mella O, Fluge Ø (2020). "Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study". Front. Med. 7: 162. doi:10.3389/fmed.2020.00162.
Source: (e.g. internet address)[edit | edit source]
doi 10.3389/fmed.2020.00162 Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study
Other information:[edit | edit source]
See also[edit | edit source]
Licensing[edit | edit source]
This file is licensed under the Creative Commons Attribution 4.0 International license. | ||
|
- ↑ Rekeland, Ingrid G.; Fosså, Alexander; Lande, Asgeir; Ktoridou-Valen, Irini; Sørland, Kari; Holsen, Mari; Tronstad, Karl J.; Risa, Kristin; Alme, Kine; Viken, Marte K.; Lie, Benedicte K.; Dahl, Olav; Mella, Olav; Fluge, Øystein (2020). "Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study". Frontiers in Medicine. 7 (162). doi:10.3389/fmed.2020.00162. ISSN 2296-858X.
File history
Click on a date/time to view the file as it appeared at that time.
Date/Time | Thumbnail | Dimensions | User | Comment | |
---|---|---|---|---|---|
current | 21:28, January 26, 2022 | 850 × 309 (67 KB) | Notjusttired (talk | contribs) | ==== Title: (or description) ==== Cyclophosphamide ME/CFS trial results extended follow-up.<br> Key: <br> (A): SF-36 Physical Function (SF-36-PF); (B) percent function level; (C): mean steps per 24hrs; CI: confidence intervals.<br/> Numbers of patie... |
You cannot overwrite this file.
File usage
There are no pages that use this file.